<DOC>
	<DOC>NCT01372761</DOC>
	<brief_summary>The purpose of this study is to assess whether multiple doses of ZGN-433 are safe and effective.</brief_summary>
	<brief_title>Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers</brief_title>
	<detailed_description>This protocol is designed to test the safety and efficacy of a drug called Beloranib (ZGN-433). It is to be tested for its ability to reduce weight in obese female subjects who are of non-childbearing potential. The study will provide information on how much ZGN-433 gets into the blood, how long it stays in the body, and how it affects other biological markers.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Obese but otherwise healthy females Nonchildbearing potential (surgically sterile, postmenopausal, or receiving implanted or injectable contraceptive for at least 3 months) BMI ≥ 30 and ≤ 50 kg/m2 Stable body weight during the past month Use of weight loss agents in the past month History of eating disorder History of gastric bypass surgery Current smokers</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Obese</keyword>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
</DOC>